Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00053105
Other study ID # CDR0000269140
Secondary ID THERADEX-AZA-I-0
Status Active, not recruiting
Phase Phase 1
First received January 27, 2003
Last updated July 4, 2009
Start date February 2002

Study information

Verified date March 2003
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.


Description:

OBJECTIVES:

- Determine the maximum tolerated dose and recommended dose of pixantrone when administered with cytarabine, methylprednisolone, and cisplatin in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

- Determine the dose-limiting toxic effects of this regimen in these patients.

- Determine the relationship between toxicity and systemic exposure to this regimen in these patients.

- Determine the safety of this regimen in these patients.

- Assess the pharmacokinetics of this regimen in these patients.

- Determine, preliminarily, the efficacy of this regimen in these patients.

OUTLINE: This is an open-label, non-randomized, multicenter, dose-escalation study of pixantrone.

Patients receive pixantrone IV over 1 hour on day 1, methylprednisolone IV over 15 minutes on days 1-5, cisplatin IV over 30 minutes on days 1-4, and cytarabine IV over 2 hours on day 5. Treatment repeats every 21 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of pixantrone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the recommended dose, which is defined as the dose preceding the MTD.

Patients are followed every 3 months.

PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 64 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) including the following:

- Diffuse large B-cell lymphoma

- Transformed NHL

- Follicular large cell lymphoma

- Peripheral T-cell lymphoma

- Unclassified aggressive histology (immunoblastic lymphoma)

- Must have received 1 to 3 prior chemotherapy treatment regimens (may include doxorubicin up to a cumulative dose of no greater than 450 mg/m^2)

- No Burkitt's lymphoma, lymphoblastic lymphoma, or mantle cell lymphoma

PATIENT CHARACTERISTICS:

Age

- 18 to 64

Performance status

- WHO 0-1

Life expectancy

- At least 3 months

Hematopoietic

- Neutrophil count at least 1,500/mm^3*

- Platelet count at least 100,000/mm^3* NOTE: *Lower values may be accepted if evidence of bone marrow involvement

Hepatic

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)**

- Alkaline phosphatase no greater than 2 times ULN**

- AST or ALT no greater than 2 times ULN**

- No history or clinical symptoms of hepatitis B or C virus NOTE: **Higher values may be accepted if evidence of liver involvement

Renal

- Creatinine no greater than 1.5 mg/dL

Cardiovascular

- LVEF at least 50% by MUGA

- No clinically significant cardiovascular abnormalities

- No New York Heart Association class II-IV heart disease

- No myocardial infarction within the past 6 months

- No severe arrhythmia

- No uncontrolled hypertension

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 6 months after study

- No history or clinical symptoms of HIV

- No clinically significant neurological abnormalities

- No serious uncontrolled infection (NCI CTC grade 3-4)

- No condition that would place the patient at undue risk or interfere with the study results

PRIOR CONCURRENT THERAPY:

Biologic therapy

- At least 3 months since prior radioimmunotherapy

Chemotherapy

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy

- At least 1 year since prior platinum or cytarabine (unless complete response to treatment)

- At least 2 years since prior fludarabine or nitrosoureas

- No prior cumulative cisplatin greater than 600 mg/m^2

Endocrine therapy

- Not specified

Radiotherapy

- See Biologic therapy

- At least 4 weeks since prior radiotherapy

- No prior radiotherapy to the whole pelvis

Surgery

- At least 1 week since prior minor surgery and recovered

- At least 4 weeks since prior major thoracic and/or abdominal surgery and recovered

Other

- At least 1 month since prior investigational drugs

- Recovered from prior therapy

- No other concurrent investigational drugs

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
cisplatin

cytarabine

methylprednisolone

pixantrone dimaleate


Locations

Country Name City State
United States Marlene and Stewart Greenebaum Cancer Center, University of Maryland Baltimore Maryland
United States Ireland Cancer Center Cleveland Ohio
United States University of Texas - MD Anderson Cancer Center Houston Texas
United States USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California
United States Boston Baskin Cancer Group, University Tennessee Memphis Tennessee
United States Highlands Oncology Group Springdale Arkansas
United States Arizona Clinical Research Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Theradex

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1